How many insider trades does FilingIQ track for JSPR?

FilingIQ tracks 53 Form 4 insider transactions for JSPR (Jasper Therapeutics, Inc.), covering filings from Sep 24, 2021 onwards. 2 of those were filed in the last 90 days.

Are JSPR insiders net buyers or net sellers?

Across the full Form 4 history for JSPR, 14 transactions (26%) were open-market purchases and 12 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does JSPR insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is JSPR in?

Jasper Therapeutics, Inc. (JSPR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $34.42M.

JSPR insider trading

Healthcare

Jasper Therapeutics, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

26% / 23%

Market cap

$34.42M

About Jasper Therapeutics, Inc.

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.

Company website: jaspertx.com

JSPR insider activity at a glance

FilingIQ has scored 53 insider transactions for JSPR since Sep 24, 2021. The most recent filing in our index is dated Jul 20, 2026.

Across the full history, 14 open-market purchases and 12 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on JSPR insider trades is 60.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live JSPR trades on FilingIQ Raw filings on SEC EDGAR

Latest JSPR Form 4 filings

MARTELL RON President and CEO

P Sep 22, 2025

WIGGANS THOMAS G

P Sep 22, 2025

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,047

UNITED THERAPEUTICS Corp

APLS 272

Apellis Pharmaceuticals, Inc.

NUVL 218

Nuvalent, Inc.

KYMR 203

Kymera Therapeutics, Inc.

HNGE 191

Hinge Health, Inc.

GH 189

Guardant Health, Inc.

Frequently asked

How many insider trades does FilingIQ track for JSPR?: FilingIQ tracks 53 Form 4 insider transactions for JSPR (Jasper Therapeutics, Inc.), covering filings from Sep 24, 2021 onwards. 2 of those were filed in the last 90 days.
Are JSPR insiders net buyers or net sellers?: Across the full Form 4 history for JSPR, 14 transactions (26%) were open-market purchases and 12 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does JSPR insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is JSPR in?: Jasper Therapeutics, Inc. (JSPR) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $34.42M.

Methodology & sources

Every JSPR insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.